TRAVERE THERAPEUTICS INC (TVTX)
Health Care · Biotechnology · NASDAQ
A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need.
What TRAVERE THERAPEUTICS INC does
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company's portfolio includes approved products and a clinical-stage pipeline targeting significant unmet medical needs in conditions like Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Themes: rare diseases, kidney disease / nephrology, drug commercialization, orphan drugs
Fundamentals
- Price$52.04 as of 2026-10-08 close
- Market cap$4.9B as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return+98.6% 2025-10-08 close $26.20 → 2026-10-08 close $52.04
- P/En/a negative earnings
- Net margin-5.2% FY2025, SEC XBRL
- ROE-22.2% FY2025, SEC XBRL
- Debt / equity24.58 as of 2026-09-02
- Revenue growth (YoY)+77.1% as of 2026-09-02
- Revenue CAGR (3y)+64.9% SEC XBRL
- Beta1.22 as of 2026-09-02
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How TVTX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How TRAVERE THERAPEUTICS INC looks technically
TRAVERE THERAPEUTICS INC (TVTX) is trading 15.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 261 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-12, breaking below its recent trading range. It is 24.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 15.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $62.13 | $62.13 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $45.24 | $45.24 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 261 trading days ago — a "golden cross", a bullish long-term signal | 261 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 31.5 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30) | 27.1 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($51.45 to $63.64) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 4.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $68.73 | $68.73 |
|---|---|---|
| From the 52-week high | it is 24.3% below its 52-week high (its highest price of the past year) | -24.3% |
| Above the 52-week low | it is 130.4% above its 52-week low (its lowest price of the past year) | +130.4% |
| Below the 52-week high | it is 24.3% below its highest point of the past year | 24.3% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-12, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-12, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $68.73 (set on 2026-09-11) | $68.73 |
| Given back of the 52-week move | over the past year its closes ranged ($24.22 to $67.52), and it has given back roughly a third of its rise from last year’s low — 36% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $39.38 to $40.76. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.8% |
| From the all-time high | it is 24.3% below its all-time high | -24.3% |
| Nearest price level | it is trading 2.3% below a resistance level at $53.21 — a price it turned at twice since 2026-07-17, most recently on 2026-08-03. Since 2024-10-08 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.3% |
| All-time low | its lowest closing price on record is $1.50 (set on 2012-11-08) | $1.50 |
| Above the all-time low | it is 3369.3% above its all-time low | +3,369% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.52 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.52 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $52.61 and $67.57 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $52.61 – $60.09 – $67.57 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (15.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 4.0% below the previous close 12 sessions ago and has not traded back through the level it left behind at 62.86 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.0% |
| Gap filled | a 2.2% gap down opened on 2026-09-08 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 22 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -9.76% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.3 percentage points (the stock lost 21.2% while the market gained 1.0%) | -22.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.7 percentage points (the stock lost 10.8% while the market gained 3.8%) | -14.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 46.0 percentage points (the stock gained 63.5% while the market gained 17.5%) | +46.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 83.6 percentage points (the stock gained 98.6% while the market gained 15.0%) | +83.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, its RSI momentum gauge is oversold (a beaten-down reading), outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.3% of the share price. | -13.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $44.85 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +16.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $61.69 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -15.6% |
Price levels it has turned at before
TVTX last closed at $52.04 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $53.21 | Resistance | 2.3% above the last close | turned there twice · 2026-07-17 to 2026-08-03 |
| $48.59 | Support | 6.6% below the last close | turned there twice · 2026-05-05 to 2026-05-29 |
| $59.93 | Resistance | 15.2% above the last close | turned there three times · 2026-06-25 to 2026-07-23 |
| $42.25 | Support | 18.8% below the last close | turned there twice · 2025-12-24 to 2026-06-02 |
| $41.21 | Support | 20.8% below the last close | turned there three times · 2026-01-05 to 2026-05-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$75.21 range $62.00 – $90.00; median $75.50
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TVTX
- Consensus EPS estimate$0.5211 next reporting period, as of 2026-10-06
- Estimate change, 30 days+$0.00876 (+1.7%) from $0.5124, on 2026-09-01, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the successful commercialization of FILSPARI (sparsentan)","Risks associated with clinical trial outcomes and regulatory approval processes","Potential for future capital requirements to fund operations and R&D"]
What changed in the latest 10-Q
AI-assisted comparison of TVTX's 10-Q filed 2026-05-04 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Footnote 2 in newer filing (filed 2026-05-04): 'On April 13, 2026, the FDA granted full (traditional) approval of FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome.'
- Footnote 3 in newer filing (filed 2026-05-04): 'Following a voluntarily pause in enrollment, we restarted enrollment activities for the pivotal Phase 3 HARMONY Study in the first quarter of 2026.'
- Section heading change in newer filing: 'FILSPARI® (sparsentan) for the treatment of IgAN' (more specific than older 'FILSPARI® (sparsentan)')
- Removed:
- Footnote 2 in older filing (filed 2025-10-30): 'In May 2025, we announced that the FDA accepted our sNDA for traditional approval of FILSPARI for the treatment of FSGS and assigned a PDUFA target action date of January 13, 2026.'
- Footnote 3 in older filing (filed 2025-10-30): 'In September 2024, we voluntarily paused enrollment in the Phase 3 HARMONY Study, as described below.'
- Text in older filing referencing 'DEARA' acronym: 'FILSPARI is a dual endothelin angiotensin receptor antagonist (DEARA).' - acronym removed in newer filing
- Reworded:
- Reference date change: 'audited financial statements and notes thereto as of and for the year ended December 31, 2024' (older, filed 2025-10-30) changed to 'year ended December 31, 2025' (newer, filed 2026-05-04)
- Reference date change: 'Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 21, 2025' (older) changed to 'year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 19, 2026' (newer)
- Quotation mark style change: 'SEC' changed to '"SEC"' in newer filing
- Text in older filing: 'FILSPARI® (sparsentan)' section heading changed to more specific 'FILSPARI® (sparsentan) for the treatment of IgAN' in newer filing
- Abbreviation formatting: '(ACE) inhibitor or angiotensin receptor blockers (ARB)' in older changed to '("ACE") inhibitor or angiotensin receptor blockers ("ARB")' in newer filing
- Abbreviation formatting: 'REMS' changed to '"REMS"' in newer filing
- Page number changed from '27' in older filing to '25' in newer filing
- Notes:
- The two texts are substantially similar in content; most differences are metadata-related (fiscal year references, filing dates) or minor formatting changes.
- The ending of both text excerpts is truncated mid-sentence regarding European Commission authorization, so comparison at the document boundary may be incomplete.
Risk Factors
- Added:
- FILSPARI approval for FSGS: full (traditional) approval granted by FDA in April 2026
- Reference to FSGS indication: "reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome"
- Language about FILSPARI being "the first and only medicine approved by the FDA for the treatment of FSGS"
- Reference to FSGS commercialization challenges: "in particular as it relates to the launch and commercialization in FSGS"
- Updated language specifying commercialization plans for both IgAN and FSGS: "and in FSGS in April 2026"
- Reference to "full (traditional) approval label for FSGS" in physician/payer response discussion
- Removed:
- Reference to ASEAN member states in the territories list (older filing stated: "including Europe, Australia, New Zealand, Japan, South Korea, Taiwan, the ASEAN member states, Brazil, Chile, Israel and the Gulf Cooperation Council countries")
- Final sentence in older filing: "We are dependent on third parties for the successful commercialization of sparsentan in certain key ter" (text appears truncated in both, but this reference is removed or reordered in newer version)
- Reworded:
- Expanded description of IgAN indication to add: "which was granted full approval by the FDA in September 2024" (separating from accelerated approval history)
- Changed from "As a product for a rare disease that had no previously-approved non-immunosuppressive treatment, the successful launch and commercialization of FILSPARI is subject to many risks" to longer formulation discussing both IgAN and FSGS separately
- Changed scope from "FILSPARI for IgAN patients" to "FILSPARI for IgAN and FSGS patients" in commercial success discussion
- Updated reference from "if the addressable patient population suffering from primary IgAN" to include both "primary IgAN or FSGS"
- Changed sales force history language from "until the commencement of our commercial launch in February 2023, no one in our sales force had promoted FILSPARI or any other medicine for the treatment of IgAN patients" to "until the commencement of our commercial launch in IgAN in February 2023, and in FSGS in April 2026, no one in our sales force had promoted FILSPARI for the treatment of IgAN or FSGS patients, respectively"
- Reference to April 10-K changed from fiscal year 2024 filed February 21, 2025 to fiscal year 2025 filed February 19, 2026
- Notes:
- Both filings appear truncated at the end of the provided excerpts, limiting assessment of potential later changes
- The older filing text provided ends with "We are dependent on third parties for the successful commercialization of sparsentan in certain key ter" suggesting possible truncation
- Full scope of all Risk Factors changes cannot be assessed due to incomplete section text in both versions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 46 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 40 sells ($66M) — 8 selling insiders
- Last 90 days · read to 2026-10-040 buys · 46 sells ($67M) — 9 selling insiders
- Last 180 days · read to 2026-10-040 buys · 82 sells ($81M) — 11 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TVTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TVTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 21,674,300
- Reported value $1,231,316,937
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TVTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TVTX had 12,955,933 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
TVTX had 13.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.38 days to cover at the same settlement.
- Reported short interest (shares) 12,955,933
- Short interest (% of shares outstanding) 13.7%
- Prior settlement (shares) 12,004,820
- Reported change 7.92%
- Days to cover (reported) 10.38
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Calliditas Therapeutics (CALT)
- Chinook Therapeutics (acquired by Novartis)
- Vera Therapeutics (VERA)
- Omeros Corporation (OMER)
- Retrophin (predecessor entity)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TVTX vs…
TRAVERE THERAPEUTICS INC is found in…
Frequently asked questions
What does TRAVERE THERAPEUTICS INC (TVTX) do?
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company's portfolio includes approved products and a clinical-stage pipeline targeting significant unmet medical needs in conditions like Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
What sector is TRAVERE THERAPEUTICS INC (TVTX) in?
TRAVERE THERAPEUTICS INC (TVTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are TRAVERE THERAPEUTICS INC's (TVTX) competitors?
Notable peers of TRAVERE THERAPEUTICS INC (TVTX) include Calliditas Therapeutics, Chinook Therapeutics (acquired by Novartis), Vera Therapeutics, Omeros Corporation and Retrophin (predecessor entity). This peer set is informational only — not financial advice.
Is TRAVERE THERAPEUTICS INC (TVTX) overbought or oversold right now?
TRAVERE THERAPEUTICS INC (TVTX) is currently in oversold territory (its 14-day RSI is 27, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TVTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.